Roberto Gallego-Pinazo, Rosa Dolz-Marco, Cristina Marín-Lambíes, Manuel Díaz-Llopis
{"title":"雷尼单抗治疗视网膜静脉闭塞后黄斑水肿的安全性和有效性。","authors":"Roberto Gallego-Pinazo, Rosa Dolz-Marco, Cristina Marín-Lambíes, Manuel Díaz-Llopis","doi":"10.4137/OED.S7264","DOIUrl":null,"url":null,"abstract":"<p><p>Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.</p>","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"4 ","pages":"15-21"},"PeriodicalIF":0.0000,"publicationDate":"2012-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/OED.S7264","citationCount":"2","resultStr":"{\"title\":\"Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.\",\"authors\":\"Roberto Gallego-Pinazo, Rosa Dolz-Marco, Cristina Marín-Lambíes, Manuel Díaz-Llopis\",\"doi\":\"10.4137/OED.S7264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.</p>\",\"PeriodicalId\":74362,\"journal\":{\"name\":\"Ophthalmology and eye diseases\",\"volume\":\"4 \",\"pages\":\"15-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4137/OED.S7264\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology and eye diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/OED.S7264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2012/1/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and eye diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/OED.S7264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/1/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.
Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
